TP53 and neoplasm: Similar to KRAS mutations, TP53 mutation-mediated NF-κB activation has an additional, non-cell autonomous impact on the TME through the secretion of a variety of pro-tumor and immunosuppressive cytokines and chemokines (Figure 2B; Mantovani et al., 2019b).